Open AccessP700: TREATMENT‐FREE REMISSION (TFR) AFTER DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML‐CP) AND DEEP MOLECULAR RESPONSE (DMR): FINAL 5‐YEAR RESULTS OF DASFREE
Author(s) -
Shah N. P.,
GarcíaGutiérrez V.,
JiménezVelasco A.,
Saussele S.,
Rea D.,
Mahon F.X.,
Levy M. Y.,
GómezCasares M. T.,
Mauro M. J.,
Sy O.,
MartinRegueira P.,
Lipton J. H.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845684.09379.3d
Subject(s) - dasatinib , discontinuation , medicine , univariate analysis , drug holiday , myeloid leukemia , oncology , imatinib , multivariate analysis , immunology , human immunodeficiency virus (hiv)